Vaccines aren't enough – working on a way to stop the polio virus for good

December 7, 2017 by Keith Grehan, The Conversation
Credit: Shutterstock

There were just 74 cases of polio reported worldwide in 2015. Thanks to a global vaccination drive, this crippling disease, which once affected hundreds of thousands of people a year, is now on the verge of extinction. The World Health Organisation estimates its eradication programme has saved around 5m people from a lifetime of paralysis.

But what happens when is finally gone? To make sure it does not come back, worldwide vaccination will have to continue. To keep producing a vaccine with current technology, we will have to retain enormous live stocks of the . This will run the risk of the virus escaping into the wild and restarting the disease – the opposite of what the vaccination programme is designed to do.

My colleagues and I are part of an international effort to come up with a new way of producing a polio vaccine that does not rely on us keeping the virus alive. The basic principle of a vaccine is to expose the body to a molecule known as an antigen that stimulates the immune system into fighting the related disease. This way, when the body encounters the actual disease, it has learnt how to react to it.

Vaccines have been in use in one form or another since the 10th century when ancient Chinese healers exposed healthy patients to powdered scabs from smallpox sufferers. Modern vaccine development relies on more controlled and safer forms of antigen exposure. In the case of virus-carried diseases like polio, the antigen is most often a weakened or deactivated version of the virus, made from a live strain.

One alternative idea is to develop a virus-like particle (VLP) assembled from the proteins that make up the coat or "capsid" of the virus. They contain no from the virus and so are sometimes called "empty capsids". This makes them safe to manufacture and use without risk of spreading the actual disease. Scientists have already used this method to develop successful vaccines against hepatitis B and human papillomavirus (HPV)

To create a VLP for poliovirus, we would like to use empty capsids that are made naturally during its normal growth cycle. The problem is that, without any genetic material inside them, these are structures are unstable when exposed to heat.

Our research group has tried a number of ways to create stable capsids for the VLPs. Our first step was to select strains of poliovirus that were inherently more resistant to heat. We repeatedly heated a sample of the virus to increasing temperatures and then exposed it to cultured cells. This enabled us to identify that were still infectious to the cells – and therefore stable – even when heated up to 57℃.

To further demonstrate these were more stable, we used a test known as a particle stability thermal release assay (PaSTRy). This involves staining the molecules that make up the virus's capsid, and the genetic material, inside with dyes that fluoresce (give off light) when exposed to the environment. Our more stable viruses didn't fluoresce after they had been heated, which showed they were still in tact.

We then isolated the mutations that made these strains so resistant to heat and used them as a model to produce empty capsids that had the desired stability. Other researchers in our group have also identified mutations that reduce the capsids' sensitivity to temperature changes and so could also generate more stable VLPs. Some of the mutant strains are proving to be even more stable than the inactivated polio vaccine currently in use.

Making the vaccine

We still need to work out the best way to use these VLPs to produce a viable . In particular, we want to develop a novel system that will produce VLPs in large numbers and with a minimum of specialised equipment. Several different systems are currently being studied including yeast, insect or plant cells. In most cases, we use a type of DNA molecule called plasmids to drive the yeast, plant or bacterial cells to produce these proteins. The VLPs are then assembled from these proteins either within the cell or during the purification process.

At the University of Leeds, we are focused on using a yeast species, Pichia pistoris. Yeast has a significant advantage over other systems because it can be grown in large quantities using fermenters. This makes it relatively simple to use them to produce vaccines on a large scale, something that has already been demonstrated for the Chikungunya .

Once we can replicate this process for the and manufacture it on a large scale, we can start looking forward to the day when we are confident the disease has been banished for good.

Explore further: Scientists prove new approach to Polio vaccines works

Related Stories

Scientists prove new approach to Polio vaccines works

February 1, 2017
Scientists have identified new ways to provide vaccines against polio, which do not require the growth of live virus for their manufacture.

Plant-produced polio vaccines could help eradicate age old disease

August 15, 2017
Plants have been used to produce a new vaccine against poliovirus in what is hoped to be a major step towards global eradication of the disease.

New technique could enable safer production of polio vaccines

January 19, 2017
A new method to produce a stable fragment of poliovirus could enable safer production of vaccines, according to a study published in PLOS Pathogens.

Syria sees first polio cases in three years: WHO

June 9, 2017
Three new cases of polio have been recorded in Syria in the first outbreak of the virus in the country since 2014, the World Health Organization and a partner initiative said.

Creating safer polio vaccine strains for the post-eradication era

December 31, 2015
While the goal of polio virus eradication is in sight, there are concerns about post-eradication manufacturing and stockpiling vaccine stores containing live virus that could escape and repopulate the environment. A study ...

WHO urges polio vaccine dose cut amid global shortage

April 28, 2017
Faced with a shortage of polio vaccine, the World Health Organization urged countries Friday to resort to smaller, fractional doses to ward off outbreaks of the crippling disease.

Recommended for you

Tibetan sheep highly susceptible to human plague, originates from marmots

August 16, 2018
In the Qinghai-Tibet plateau, one of the region's highest risk areas for human plague, Himalayan marmots are the primary carriers of the infectious bacterium Y. pestis. Y. pestis infection can be transmitted to humans and ...

Autoimmunity plays role in development of COPD, study finds

August 16, 2018
Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information ...

Reliable point-of-care blood test can help prevent toxoplasmosis

August 16, 2018
A recent study, performed in Chicago and Rabat, Morocco, found that a novel finger-prick test for infection with the parasite Toxoplasma gondii during pregnancy—and many other potential applications—is 100 percent sensitive ...

Scientists identify nearly 200 potential tuberculosis drug targets

August 16, 2018
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost ...

First mouse model to mimic lung disease could speed discovery of more effective treatments

August 16, 2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability ...

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.